Oxidant stress in HIV-infected women from the Women's Interagency HIV Study

Antiviral Therapy

Volumn 14, Issue 6, 2009, Pages 763-769

  Glesby, Marshall J ^a   Hoover, Donald R ^b   Raiszadeh, Farbod ^c   Lee, Irene ^d   Shi, Qiuhu ^d,e   Milne, Ginger ^f   Sanchez, Stephanie C ^f   Gao, Wei ^g   Kaplan, Robert C ^g   Morrow, Jason D ^f   Anastos, Kathryn ^g  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^d Analytic Solutions LLC   (United States)

^e NEW YORK MEDICAL COLLEGE   (United States)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CD4 ANTIGEN; EFAVIRENZ; FIBRIC ACID DERIVATIVE; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPROSTANE DERIVATIVE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ABDOMINAL OBESITY; ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; UNITED STATES; VIREMIA; WAIST CIRCUMFERENCE;

ADULT; ATHEROSCLEROSIS; CROSS-SECTIONAL STUDIES; F2-ISOPROSTANES; FEMALE; HIV INFECTIONS; HOMOCYSTEINE; HUMANS; MIDDLE AGED; OXIDANTS; OXIDATIVE STRESS; RISK FACTORS;

EID: 72049123481     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1290     Document Type: Article

References (23)

1. Morrow JD. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol 2005; 25:279-286.
2. Trushina E, McMurray CT. Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. Neuroscience 2007; 145:1233-1248. (Pubitemid 46602738)
3. Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 2004; 44:239-267.
4. Meigs JB, Larson MG, Fox CS, Keaney JF, Jr., Vasan RS, Benjamin EJ. Association of oxidative stress, insulin resistance, and diabetes risk phenotypes: the Framingham Offspring Study. Diabetes Care 2007; 30:2529-2535.
5. Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. Cell 2005; 120:483-495.
6. 2-isoprostanes in biological fluids and tissues as a measure of oxidant stress. Methods Enzymol 2007; 433:113-126.
7. McComsey GA, Morrow JD. Lipid oxidative markers are significantly increased in lipoatrophy but not in sustained asymptomatic hyperlactatemia. J Acquir Immune Defic Syndr 2003; 34:45-49.
8. Hulgan T, Hughes M, Sun X, et al. Oxidant stress and peripheral neuropathy during antiretroviral therapy: an AIDS clinical trials group study. J Acquir Immune Defic Syndr 2006; 42:450-454. (Pubitemid 44050892)
9. Gross M, Steffes M, Jacobs DR, Jr., et al. Plasma F2-isoprostanes and coronary artery calcification: the CARDIA Study. Clin Chem 2005; 51:125-131. (Pubitemid 40024021)
10. Zou CG, Banerjee R. Homocysteine and redox signaling. Antioxid Redox Signal 2005; 7:547-559.
11. Voutilainen S, Morrow JD, Roberts LJ, et al. Enhanced in vivo lipid peroxidation at elevated plasma total homocysteine levels. Arterioscler Thromb Vasc Biol 1999; 19:1263-1266. (Pubitemid 29227646)
12. Weiss N. Mechanisms of increased vascular oxidant stress in hyperhomocysteinemia and its impact on endothelial function. Curr Drug Metab 2005; 6:27-36. (Pubitemid 40277879)
13. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology 1998; 9:117-125.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419. (Pubitemid 15018832)
15. Strickler HD, Howard AA, Peters M, et al. The insulin-like growth factor axis and risk of liver disease in hepatitis C virus/HIV-co-infected women. AIDS 2008; 22:527-531. (Pubitemid 351317295)
16. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43:1317-1325. (Pubitemid 43980111)
17. Hulgan T, Morrow J, D'Aquila RT, et al. Oxidant stress is increased during treatment of human immunodeficiency virus infection. Clin Infect Dis 2003; 37:1711-1717. (Pubitemid 37549961)
18. Block G, Dietrich M, Norkus EP, et al. Factors associated with oxidative stress in human populations. Am J Epidemiol 2002; 156:274-285. (Pubitemid 34810481)
19. Dageforde LA, Shintani A, Haas D, et al. NNRTI use may be associated with decreased oxidant stress during HIV therapy. 14th Conference on Retroviruses and Opportunistic Infections. 25-28 February 2007, Los Angeles, CA, USA. Abstract 798.
20. The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354:1567-1577.
21. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354:1578-1588.
22. Sanyal AJ. Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2005; 2:46-53. (Pubitemid 40812527)
23. Ishizaka N, Ishizaka Y, Takahashi E, et al. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet 2002; 359:133-135. (Pubitemid 34112545)